Seborrheic dermatitis: is there room for systemic corticosteroids?

Mesquita, Kleyton de Carvalho; Igreja, Ana Carolina de Souza Machado; Costa, Izelda Maria Carvalho

doi:10.1590/s0365-05962012000300034

Cited by 2 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the 21 publications identified, nine were for itraconazole, three for terbinafine, three for fluconazole, two for ketoconazole, and one for each of pramiconazole, predinisone, isotretinoin and homeopathic mineral therapy . Case reports and studies without the full text availability were not evaluated for quality.…”

Section: Resultsmentioning

confidence: 99%

“…Five studies were RCTs with a MQS varying between 13.5 and 22.0 on a possible 28 point scale. Ten were open studies with a MQS varying between 8.5 and 13.5 and six were case reports …”

Section: Resultsmentioning

confidence: 99%

“…Mesquita et al . reported a case that involved the successful treatment of SD with the systemic corticosteroid prednisone in a 43‐year‐old man . The patient had severe SD and was unresponsive to topical therapy.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Systematic Review of Oral Treatments for Seborrheic Dermatitis

Gupta

Richardson

Paquet

2013

Acad Dermatol Venereol

View full text Add to dashboard Cite

Seborrheic dermatitis (SD) is normally treated with topical corticosteroids and antifungals. Oral therapies can be prescribed in severe or unresponsive cases. This review aims to assess the quantity and quality of published reports on oral therapies for SD. MEDLINE and Embase databases and the reference listings of publications were searched for any publication using oral treatment for SD. The quality of the included publications was assessed using a modified 27 item checklist by Downs and Black. Twenty-one publications (randomized controlled trials, open trials and case reports) covering eight oral therapies (itraconazole, terbinafine, fluconazole, ketoconazole, pramiconazole, prednisone, isotretinoin and homeopathic mineral therapy) were identified. Most of the publications investigated oral antifungals and the quality of the evidence was generally low. The clinical efficacy outcome reported varied considerably between the studies, preventing statistical analysis and direct comparison between treatments. However, ketoconazole therapy was associated with more relapses compared with other treatments. Itraconazole dosing regimen for SD was generally 200 mg/day for the first week of the month followed by 200 mg/day for the first 2 days for 2-11 months. Terbinafine was prescribed at 250 mg/day either as a continuous (4-6 weeks) or as an intermittent regimen (12 days per month) for 3 months. Fluconazole has administered daily (50 mg/day for 2 weeks) or weekly (200-300 mg) for 2-4 weeks. Ketoconazole dosing regimen was 200 mg daily for 4 weeks. Finally, a single 200 mg dose of pramiconazole was administered to patients. This review also highlights key areas for consideration when designing future studies.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Five studies were RCTs with a MQS varying between 13.5 and 22.0 on a possible 28 point scale. Ten were open studies with a MQS varying between 8.5 and 13.5 and six were case reports …”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Systematic Review of Oral Treatments for Seborrheic Dermatitis

Gupta

Richardson

Paquet

2013

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Treatment of seborrheic dermatitis: a comprehensive review

Borda

Perper

Keri

2018

Journal of Dermatological Treatment

View full text Add to dashboard Cite

Seborrheic dermatitis (SD) is a chronic, recurring inflammatory skin disorder that manifests as erythematous macules or plaques with varying levels of scaling associated with pruritus. The condition typically occurs as an inflammatory response to Malassezia species and tends to occur on seborrheic areas, such as the scalp, face, chest, back, axilla, and groin areas. SD treatment focuses on clearing signs of the disease; ameliorating associated symptoms, such as pruritus; and maintaining remission with long-term therapy. Since the primary underlying pathogenic mechanisms comprise Malassezia proliferation and inflammation, the most commonly used treatment is topical antifungal and anti-inflammatory agents. Other broadly used therapies include lithium gluconate/succinate, coal tar, salicylic acid, selenium sulfide, sodium sulfacetamide, glycerin, benzoyl peroxide, aloe vera, mud treatment, phototherapy, among others. Alternative therapies have also been reported, such as tea tree oil, Quassia amara, and Solanum chrysotrichum. Systemic therapy is reserved only for widespread lesions or in cases that are refractory to topical treatment. Thus, in this comprehensive review, we summarize the current knowledge on SD treatment and attempt to provide appropriate directions for future cases that dermatologists may face.

show abstract

Seborrheic dermatitis: is there room for systemic corticosteroids?

Cited by 2 publications

References 4 publications

Systematic Review of Oral Treatments for Seborrheic Dermatitis

Systematic Review of Oral Treatments for Seborrheic Dermatitis

Treatment of seborrheic dermatitis: a comprehensive review

Contact Info

Product

Resources

About